摘要
目的探讨多西他赛联合顺铂和5-氟尿嘧啶治疗晚期复治食管癌的临床疗效。方法选取2012年5月至2016年5月间云南省肿瘤医院收治的80例晚期复治食管癌患者,采用等距随机抽样法分为观察组与对照组,每组40例。观察者患者采用多西他赛联合顺铂和5-氟尿嘧啶治疗,对照组患者采用多西他赛联合顺铂治疗,2个疗程后比较临床疗效。结果观察组患者治疗总有效率为62.5%,生活质量总分(88.14士1.21)分,对照组患者总有效率为47.5%,生活质量总分(75.33±1.25)分,两组比较差异均有统计学意义(均P<0.05);对照组患者不良反应发生率为15.0%,观察组患者为17.5%,两组比较差异无统计学意义(P>0.05)。结论多西他赛联合顺铂与5-氟尿嘧啶化疗方案治疗晚期复治食管癌疗效显著,可作为首选治疗方案推广使用。
Objective To analyze the clinical efficacy of docetaxel combined with 5-fluorouracil and cisplatin in the treatment of advanced esophageal cancer.Methods From May 2012 to May 2016,select 80 patients with advanced esophageal cancer treated at Yunnan Tumor Hospital,The Third Affiliated Hospital of Kunming Medical University.Using systematic random sampling,patients were divided into an observation group and a control group,with 40 patients in each group.Patients in the observation group received docetaxel combined with 5-fluorouracil and cisplatin and patients in the control group received docetaxel plus.Clinical efficacy was compared after 2 courses.Results The overall efficiency and overall quality of life score was 62.5% and（88.14±1.21） points for the observation group repectively and 47.5% and（75.33±1.25） points repectively for the control group（P〈0.05）.The adverse reaction rate was 15.0% for the observation group and 17.5% for the control group（P〉0.05）.Conclusion Docetaxel combined with 5-fluorouracil and cisplatin in the treatment of advanced esophageal cancer has obvious curative efficacy,which can be popularized as the primary therapy for advanced esophageal.
作者
王轶珊
田青
李云霞
赵明利
吕东津
毕清
WANG Yi-shan TIAN Qing LI Yun-xia ZHAO Ming-li LYU Dong-jin BI Qing(Department of Oncology,Yunnan Tumor Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming 650108, China)
出处
《中国肿瘤临床与康复》
2017年第1期59-61,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
